Announced
Completed
Financials
Sources
RNS Announcement
hVIVO -
RNS Announcement
Open Orphan -
Offer Update
Open Orphan -
Publication and Posting of Rule 15 Proposals
Open Orphan -
Second Closing of the Offer
Open Orphan -
Completion Announcement
Open Orphan -
Offer Wholly Unconditional
Open Orphan -
Completion of the compulsory acquisition of remaining hVIVO shares
Open Orphan -
Tags
Friendly
clinical trials
Acquisition
Single Bidder
United Kingdom
Majority
Merger
Biotechnology
Public
Completed
Synopsis
Open Orphan, a Dublin-listed pharma services company, completed its merger with hVIVO, a clinical trial business that can accelerate drug and vaccine development, in a £13m deal. "The merger of Open Orphan and hVIVO is a key milestone in the execution of our strategy to become a larger-scale specialist pharma services business and in complementary segments where specialist skills and know-how command higher margins," Cathal Friel, Open Orphan CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.